Autopsy report · NCT03739606

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

“RSS recommendation”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

City of Hope Medical Center

Sponsor type

University, hospital or other

Conditions

Acute Biphenotypic Leukemia; Acute Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hairy Cell Leukemia; Interleukin-3 Receptor Subunit Alpha Positive; Recurrent Acute Lymphoblastic Leukemia

Interventions

Anti-CD123/CD3 Monoclonal Antibody MGD006

Participants

0

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.